Reviewing Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) & Tilray Brands (NASDAQ:TLRY)

Tilray Brands (NASDAQ:TLRY) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Institutional and Insider Ownership

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Tilray Brands has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500.

Profitability

This table compares Tilray Brands and Shionogi & Co., Ltd. Unsponsored ADR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
Shionogi & Co., Ltd. Unsponsored ADR	46.67%	16.13%	12.09%

Earnings & Valuation

This table compares Tilray Brands and Shionogi & Co., Ltd. Unsponsored ADR”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$210.48 million	2.34	-$121.40 million	($1.08)	-3.34
Shionogi & Co., Ltd. Unsponsored ADR	$3.32 billion	4.51	$1.35 billion	$1.00	8.80

Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Shionogi & Co., Ltd. Unsponsored ADR, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Tilray Brands and Shionogi & Co., Ltd. Unsponsored ADR, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	2	2	2	1	2.29
Shionogi & Co., Ltd. Unsponsored ADR	0	1	0	2	3.33

Tilray Brands presently has a consensus price target of $7.00, indicating a potential upside of 93.91%. Given Tilray Brands’ higher possible upside, equities research analysts plainly believe Tilray Brands is more favorable than Shionogi & Co., Ltd. Unsponsored ADR.

Summary

Shionogi & Co., Ltd. Unsponsored ADR beats Tilray Brands on 10 of the 15 factors compared between the two stocks.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.